
Vibol Tan
Examiner (ID: 4117, Phone: (571)272-1811 , Office: P/2844 )
| Most Active Art Unit | 2819 |
| Art Unit(s) | 2844, 2819 |
| Total Applications | 2718 |
| Issued Applications | 2530 |
| Pending Applications | 32 |
| Abandoned Applications | 163 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16696638
[patent_doc_number] => 10947218
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Aminopyridine derivatives and their use as selective ALK-2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/884666
[patent_app_country] => US
[patent_app_date] => 2020-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 19
[patent_no_of_words] => 31986
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884666
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/884666 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | May 26, 2020 | Issued |
Array
(
[id] => 17378073
[patent_doc_number] => 11236070
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-01
[patent_title] => Chemical process
[patent_app_type] => utility
[patent_app_number] => 16/874613
[patent_app_country] => US
[patent_app_date] => 2020-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1621
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16874613
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/874613 | Chemical process | May 13, 2020 | Issued |
Array
(
[id] => 16512876
[patent_doc_number] => 20200392134
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => METHOD FOR PURIFYING 2-[[2-[[[3-(4-CHLOROPHENYL)-8-METHYL-8-AZABICYCLO-[3.2.1]-OCT-2-YL]METHYL](2-MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOL-[1R-(EXO-EXO)]TRIHYDROCHLORIDE
[patent_app_type] => utility
[patent_app_number] => 15/930275
[patent_app_country] => US
[patent_app_date] => 2020-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930275
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/930275 | METHOD FOR PURIFYING 2-[[2-[[[3-(4-CHLOROPHENYL)-8-METHYL-8-AZABICYCLO-[3.2.1]-OCT-2-YL]METHYL](2-MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOL-[1R-(EXO-EXO)]TRIHYDROCHLORIDE | May 11, 2020 | Abandoned |
Array
(
[id] => 16589244
[patent_doc_number] => 10898486
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-26
[patent_title] => Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
[patent_app_type] => utility
[patent_app_number] => 16/864153
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 8647
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864153
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/864153 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | Apr 29, 2020 | Issued |
Array
(
[id] => 16252078
[patent_doc_number] => 20200261452
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-20
[patent_title] => CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/864148
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8571
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864148
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/864148 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | Apr 29, 2020 | Issued |
Array
(
[id] => 16236738
[patent_doc_number] => 20200253972
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/864020
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8556
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864020
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/864020 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | Apr 29, 2020 | Issued |
Array
(
[id] => 16206428
[patent_doc_number] => 20200239418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => HETEROCYCLIC COMPOUND
[patent_app_type] => utility
[patent_app_number] => 16/847761
[patent_app_country] => US
[patent_app_date] => 2020-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847761
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/847761 | Heterocyclic compound | Apr 13, 2020 | Issued |
Array
(
[id] => 16421829
[patent_doc_number] => 20200347027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => CRYSTALLINE FORMS OF LENALIDOMIDE
[patent_app_type] => utility
[patent_app_number] => 16/832112
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16832112
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/832112 | Crystalline forms of lenalidomide | Mar 26, 2020 | Issued |
Array
(
[id] => 16343465
[patent_doc_number] => 20200308115
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/831370
[patent_app_country] => US
[patent_app_date] => 2020-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34183
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16831370
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/831370 | Beta adrenergic agonist and methods of using the same | Mar 25, 2020 | Issued |
Array
(
[id] => 16572877
[patent_doc_number] => 10894790
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-19
[patent_title] => Production method of thiazole derivative
[patent_app_type] => utility
[patent_app_number] => 16/822626
[patent_app_country] => US
[patent_app_date] => 2020-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 9270
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822626
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/822626 | Production method of thiazole derivative | Mar 17, 2020 | Issued |
Array
(
[id] => 16156375
[patent_doc_number] => 20200216420
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-09
[patent_title] => HISTONE DEMETHYLASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/819875
[patent_app_country] => US
[patent_app_date] => 2020-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819875
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/819875 | Histone demethylase inhibitors | Mar 15, 2020 | Issued |
Array
(
[id] => 16832081
[patent_doc_number] => 11008321
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-18
[patent_title] => Crystalline form of an avibactam derivative
[patent_app_type] => utility
[patent_app_number] => 16/813930
[patent_app_country] => US
[patent_app_date] => 2020-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 18462
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813930
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/813930 | Crystalline form of an avibactam derivative | Mar 9, 2020 | Issued |
Array
(
[id] => 16832081
[patent_doc_number] => 11008321
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-18
[patent_title] => Crystalline form of an avibactam derivative
[patent_app_type] => utility
[patent_app_number] => 16/813930
[patent_app_country] => US
[patent_app_date] => 2020-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 18462
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813930
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/813930 | Crystalline form of an avibactam derivative | Mar 9, 2020 | Issued |
Array
(
[id] => 16770821
[patent_doc_number] => 10981909
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
[patent_app_type] => utility
[patent_app_number] => 16/813021
[patent_app_country] => US
[patent_app_date] => 2020-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 58
[patent_no_of_words] => 45642
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 288
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813021
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/813021 | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | Mar 8, 2020 | Issued |
Array
(
[id] => 17134782
[patent_doc_number] => 11136328
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-05
[patent_title] => 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
[patent_app_type] => utility
[patent_app_number] => 16/810258
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 31
[patent_no_of_words] => 49282
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810258
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810258 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | Mar 4, 2020 | Issued |
Array
(
[id] => 16642039
[patent_doc_number] => 10919873
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-16
[patent_title] => Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/807053
[patent_app_country] => US
[patent_app_date] => 2020-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 6982
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16807053
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/807053 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | Mar 1, 2020 | Issued |
Array
(
[id] => 17435849
[patent_doc_number] => 11261161
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-01
[patent_title] => Processes for preparing ASK1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/795329
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 26614
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 268
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795329
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/795329 | Processes for preparing ASK1 inhibitors | Feb 18, 2020 | Issued |
Array
(
[id] => 16012553
[patent_doc_number] => 20200181119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => (S)-N-(3-6-ISOPROPOXYPYRIDIN-3-3YL)-1H-INDAZOL-5-YL)-1-(2-(4-4(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3,6-DIHYDROPYRIDIN-1(2H-YL)-2-OXOETHYL)-3(METHYLTHIO)PYRROLIDINE-3-CARBOXAMIDE COMPOSITIONS FOR PHARMACEUTICAL PREPARATIONS
[patent_app_type] => utility
[patent_app_number] => 16/789123
[patent_app_country] => US
[patent_app_date] => 2020-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3121
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16789123
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/789123 | (S)-N-(3-6-isopropoxypyridin-3-3YL)-1H-indazol-5-yl)-1-(2-(4-4(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H-yl)-2-oxoethyl)-3(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | Feb 11, 2020 | Issued |
Array
(
[id] => 17236590
[patent_doc_number] => 11180461
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-23
[patent_title] => Triazoles as Kv3 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/785083
[patent_app_country] => US
[patent_app_date] => 2020-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33730
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16785083
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/785083 | Triazoles as Kv3 inhibitors | Feb 6, 2020 | Issued |
Array
(
[id] => 16222644
[patent_doc_number] => 20200247760
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => Compounds, Compositions and Methods for Treatment of Myopia
[patent_app_type] => utility
[patent_app_number] => 16/779188
[patent_app_country] => US
[patent_app_date] => 2020-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12903
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779188
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/779188 | Compounds, compositions and methods for treatment of myopia | Jan 30, 2020 | Issued |